Article (Scientific journals)
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Schmid, Peter; Sablin, Marie-Paule; Bergh, Jonas et al.
2021In Breast cancer research : BCR, 23 (1), p. 8
Peer reviewed


Full Text
A phase Ib-II study of xentuzumab, an IGF-neutralising antibody... - article GJ.pdf
Publisher postprint (1.05 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to


Keywords :
Breast cancer; HER2-negative; Hormone receptor-positive; Insulin-like growth factor; Xentuzumab; oncology
Abstract :
[en] BACKGROUND: Xentuzumab-a humanised IgG1 monoclonal antibody-binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xentuzumab plus everolimus and exemestane in hormone receptor-positive, locally advanced and/or metastatic breast cancer (LA/MBC). METHODS: Patients with hormone receptor-positive/HER2-negative LA/MBC resistant to non-steroidal aromatase inhibitors were enrolled. Maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of xentuzumab/everolimus/exemestane were determined in phase I (single-arm, dose-escalation). In phase II (open-label), patients were randomised 1:1 to the RP2D of xentuzumab/everolimus/exemestane or everolimus/exemestane alone. Randomisation was stratified by the presence of visceral metastases. Primary endpoint was progression-free survival (PFS). RESULTS: MTD was determined as xentuzumab 1000 mg weekly plus everolimus 10 mg/day and exemestane 25 mg/day. A total of 140 patients were enrolled in phase II (70 to each arm). Further recruitment was stopped following an unfavourable benefit-risk assessment by the internal Data Monitoring Committee appointed by the sponsor. Xentuzumab was discontinued; patients could receive everolimus/exemestane if clinically indicated. Median PFS was 7.3 months (95% CI 3.3-not calculable) in the xentuzumab/everolimus/exemestane group and 5.6 months (3.7-9.1) in the everolimus/exemestane group (hazard ratio 0.97, 95% CI 0.57-1.65; P = 0.9057). In a pre-specified subgroup of patients without visceral metastases at screening, xentuzumab/everolimus/exemestane showed evidence of PFS benefit versus everolimus/exemestane (hazard ratio 0.21 [0.05-0.98]; P = 0.0293). Most common any-cause adverse events in phase II were diarrhoea (29 [41.4%] in the xentuzumab/everolimus/exemestane group versus 20 [29.0%] in the everolimus/exemestane group), mucosal inflammation (27 [38.6%] versus 21 [30.4%]), stomatitis (24 [34.3%] versus 24 [34.8%]), and asthenia (21 [30.0%] versus 24 [34.8%]). CONCLUSIONS: Addition of xentuzumab to everolimus/exemestane did not improve PFS in the overall population, leading to early discontinuation of the trial. Evidence of PFS benefit was observed in patients without visceral metastases when treated with xentuzumab/everolimus/exemestane, leading to initiation of the phase II XENERA™-1 trial (NCT03659136). TRIAL REGISTRATION:, NCT02123823 . Prospectively registered, 8 March 2013.
Disciplines :
Author, co-author :
Schmid, Peter
Sablin, Marie-Paule
Bergh, Jonas
Im, Seock-Ah
Lu, Yen-Shen
Martínez, Noelia
Neven, Patrick
Lee, Keun Seok
Morales, Serafín
Pérez-Fidalgo, J. Alejandro
Adamson, Douglas
Gonçalves, Anthony
Prat, Aleix
Jerusalem, Guy  ;  Université de Liège - ULiège > Département des sciences cliniques > Oncologie
Schlieker, Laura
Espadero, Rosa-Maria
Bogenrieder, Thomas
Huang, Dennis Chin-Lun
Crown, John
Cortés, Javier
More authors (10 more) Less
Language :
Title :
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Publication date :
Journal title :
Breast cancer research : BCR
Volume :
Issue :
Pages :
Peer reviewed :
Peer reviewed
Available on ORBi :
since 02 February 2021


Number of views
53 (6 by ULiège)
Number of downloads
3 (3 by ULiège)

Scopus citations®
Scopus citations®
without self-citations


Similar publications

Contact ORBi